基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识（2021版）

摘要/Abstract

摘要： 多达半数的肝细胞癌初诊时即为晚期,而晚期肝细胞癌缺乏有效的治疗措施,预后极差。近年来,免疫检查点抑制剂联合抗血管生成靶向药物治疗晚期肝细胞癌已显示出较高的有效率,显著延长了患者的生存期,也为序贯外科根治性手术提供了可能。为了提高肝癌总体人群的远期生存率,实现《“健康中国2030”规划纲要》癌症总体5年生存率提高15%的目标,中华预防医学会肝胆胰疾病预防与控制专业委员会、中国抗癌协会肝癌专业委员会、北京医学会外科学分会肝脏学组委托《中华肝胆外科杂志》编辑部组织国内相关专业专家,就免疫联合靶向转化治疗晚期肝细胞癌的相关要点开展了深入的讨论并形成初步共识,以指导临床实践,规范医疗行为,推动学科发展。

关键词: 癌, 肝细胞, 分子靶向治疗, 肝切除术, 免疫检查点抑制剂, 转化治疗

Abstract: As many as half of hepatocellular carcinomas are at advanced stage when first diagnosed, and advanced stage hepatocellular carcinoma lacks effective treatment which leads to a very poor prognosis. In recent years, Immune checkpoint inhibitors combined with anti-angiogenesis drugs has shown a high effective rate in the treatment of advanced hepatocellular carcinoma, which significantly prolongs the overall survival of the patients and also provides the possibility of the sequent radical surgery? In order to improve the long-term survival rate of the liver cancer patients and achieve the goal of increasing the 5-year overall survival rate by 15% according to "Healthy China 2030" plan, the Hepatobiliary and Pancreatic Disease Prevention and Control Committee of the Chinese Preventive Medicine Association and the Liver Cancer Committee of the Chinese Anti-Cancer Association have deep discussions on the key points of medical treatment of advanced hepatocellular carcinoma and a preliminary consensus was formed to guide clinical practice, standardize medical behavior, and promote disciplines.

Key words: Cancer, hepatocytes, Molecular targeted therapy, Hepatectomy, Immune checkpoint inhibitors, Translational therapy

中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国抗癌协会肝癌专业委员会, 北京医学会外科学分会肝脏学组, 《中华肝胆外科杂志》编辑委员会. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识（2021版）[J]. 肝癌电子杂志, 2021, 8(2): 6-15.

Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association; Chinese Society of Liver Cancer, Chinese Anti-Cancer Association; Liver Study Group of Surgery Committee of Beijing Medical Association; Editorial Board of Chinese Journal of Hepatobiliary Surgery. Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2021 Edition)[J]. Electronic Journal of Liver Tumor, 2021, 8(2): 6-15.

参考文献

[1] AN L, ZENG HM, ZHENG RS, et al.Liver cancer epidemiology in China, 2015[J]. Zhonghua Zhong Liu Za Zhi, 2019, 41(10): 721-727.
[2] SUNG H, FERLAY J, SIEGEL RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71:209-249.
[3] LLOVET JM, ZUCMAN-ROSSI J, PIKARSKY E, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2016, 2: 16018.
[4] ZHOU J, SUN H, WANG Z, et al.Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition)[J]. Liver Cancer, 2020, 9(6): 682-720.
[5] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[6] CABIBBO G, ENEA M, ATTANASIO M, et al.A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma[J]. Hepatology, 2010, 51(4): 1274-1283.
[7] CABIBBO G, MAIDA M, GENCO C, et al.Natural history of untreatable hepatocellular carcinoma: a retrospective cohort study[J]. World J Hepatol, 2012, 4(9): 256-261.
[8] XIANG X, ZHONG JH, WANG YY, et al.Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma[J]. Clin Transl Oncol, 2017, 19(7): 891-897.
[9] GIANNINI EG, FARINATI F, CICCARESE F, et al.Prognosis of untreated hepatocellular carcinoma[J]. Hepatology, 2015, 61(1): 184-190.
[10] YEN YH, CHENG YF, WANG JH, et al.Real world clinical practice in treating advanced hepatocellular carcinoma: when East meets West[J]. PLoS One, 2020, 15(3): e0230005.MOKDAD AA, SINGAL AG, MARRERO JA, et al. Vascular invasion and metastasis is predictive of outcome in Barcelona clinic liver cancer stage C hepatocellular carcinoma[J]. J Natl Compr Canc Netw, 2017, 15(2): 197-204.
[11] NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers Version 1[EB/OL].[2021-03-05]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1438.
[12] FINN RS, IKEDA M, ZHU AX, et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970.
[13] FINN RS, QIN S, IKEDA M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[14] QADAN M, KOTHARY N, SANGRO B, et al.The treatment of hepatocellular carcinoma with portal vein tumor thrombosis[J]. Am Soc Clin Oncol Educ Book, 2020, 40: 1-8.
[15] ZHANG T, ZHANG L, XU Y, et al.Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma[J]. Am J Cancer Res, 2020, 10(6): 1658-1667.
[16] LEWANDOWSKI RJ, MULCAHY MF, KULIK LM, et al.Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort[J]. Radiology, 2010, 255(3): 955-965.
[17] HYUN MH, LEE YS, KIM JH, et al.Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies[J]. Hepatology, 2018, 68(3): 977-993.
[18] PINTER M, HUCKE F, GRAZIADEI I, et al.Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib[J]. Radiology, 2012, 263(2): 590-599.
[19] LE Y, SHEN JX, ZHANG YF, et al.Transarterial chemoembolization related to good survival for selected patients with advanced hepatocellular carcinoma[J]. J Cancer, 2019, 10(3): 665-671.
[20] CHOI JW, KIM HC, LEE JH, et al.Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus[J]. Eur Radiol, 2017, 27(4): 1448-1458.
[21] ZHONG JH, KE Y, GONG WF, et al.Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014, 260(2): 329-340.
[22] GORODETSKI B, CHAPIRO J, SCHERNTHANER R, et al.Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization[J]. Eur Radiol, 2017, 27(2): 526-535.
[23] CHUNG GE, LEE JH, KIM HY, et al.Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology, 2011, 258(2): 627-634.
[24] LEE SW, LEE TY, PENG YC, et al.The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma[J]. J Dig Dis, 2020, 21(5): 287-292.
[25] FAN W, YUAN G, FAN H, et al.Apatinib combined with transarterial chemoembolization in patients with hepatocellular carcinoma and portal vein tumor thrombus: a multicenter retrospective study[J]. Clin Ther, 2019, 41(8): 1463-1476.
[26] GANS JH, LIPMAN J, GOLOWA Y, et al.Hepatic cancers overview: surgical and chemotherapeutic options, how do Y-90 microspheres fit in?[J]. Semin Nucl Med, 2019, 49(3): 170-181.
[27] SALEM R, LEWANDOWSKI RJ, MULCAHY MF, et al.Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes[J]. Gastroenterology, 2010, 138(1): 52-64.
[28] IÑARRAIRAEGUI M, THURSTON KG, BILBAO JI, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis[J]. J Vasc Interv Radiol, 2010, 21(8): 1205-1212.
[29] SANGRO B, CARPANESE L, CIANNI R, et al.Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation[J]. Hepatology, 2011, 54(3): 868-878.
[30] CHOW P, GANDHI M, TAN SB, et al.SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma[J]. J Clin Oncol, 2018, 36(19): 1913-1921.
[31] MEI J, LI SH, WANG QX, et al.Resection vs. sorafenib for hepatocellular carcinoma with macroscopic vascular invasion: a real world, propensity score matched analytic study[J]. Front Oncol, 2020, 10: 573.
[32] GRAMENZI A, GOLFIERI R, MOSCONI C, et al.Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis[J]. Liver Int, 2015, 35(3): 1036-1047.
[33] COSTENTIN CE, DECAENS T, LAURENT A, et al.Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: a propensity score analysis[J]. Liver Int, 2017, 37(12): 1869-1876.
[34] KUO YH, WU IP, WANG JH, et al.The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis[J]. Invest New Drugs, 2018, 36(2): 307-314.
[35] LEE SW, LEE TY, PENG YC, et al.Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: a study on prognostic factors of the viral and tumor status[J]. Medicine (Baltimore), 2019, 98(44): e17692.
[36] HE M, LI Q, ZOU R, et al.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960.
[37] LYU N, KONG Y, MU L, et al.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 60-69.
[38] QUE J, LIN CH, LIN LC, et al.Challenges of BCLC stage C hepatocellular carcinoma: results of a single-institutional experience on stereotactic body radiation therapy[J]. Medicine (Baltimore), 2020, 99(32): e21561.
[39] SU TS, LI LQ, MENG WW, et al.Long-term survival analysis of transarterial chemoembolization plus radiotherapy vs. radiotherapy for hepatocellular carcinoma with macroscopic vascular invasion[J]. Front Oncol, 2020, 10: 1205.
[40] LIU BJ, GAO S, ZHU X, et al.Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma[J]. World J Gastrointest Oncol, 2020, 12(6): 663-676.
[41] KIM YJ, JUNG J, JOO JH, et al.Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: necessity to subclassify Barcelona clinic liver cancer stage C[J]. Radiother Oncol, 2019, 141: 95-100.
[42] HAN KH, SEONG J, KIM JK, et al.Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis[J]. Cancer, 2008, 113(5): 995-1003.
[43] LEE HS, CHOI GH, CHOI JS, et al.Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy[J]. Ann Surg Oncol, 2014, 21(11): 3646-3653.
[44] LONG J, ZHENG JS, SUN B, et al.Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study[J]. Hepatol Int, 2016, 10(1): 175-184.
[45] YAU T, HSU C, KIM TY, et al.Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis[J]. J Hepatol, 2019, 71(3): 543-552.
[46] XIA F, WU LL, LAU WY, et al.Adjuvant sorafenib after heptectomy for Barcelona clinic liver cancer-stage C hepatocellular carcinoma patients[J]. World J Gastroenterol, 2016, 22(23): 5384-5392.
[47] CHANG WT, KAO WY, CHAU GY, et al.Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection?[J]. Surgery, 2012, 152(5): 809-820.
[48] CAO L, CHEN J, DUAN T, et al.Diffusion kurtosis imaging (DKI) of hepatocellular carcinoma: correlation with microvascular invasion and histologic grade[J]. Quant Imaging Med Surg, 2019, 9(4): 590-602.
[49] KOH YX, TAN HL, LYE WK, et al.Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona clinic liver cancer stage hepatocellular carcinoma: a critical appraisal of the evidence[J]. World J Hepatol, 2018, 10(6): 433-447.
[50] LI J, HOU Y, CAI XB, et al.Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(15): 4034-4040.
[51] LIM C, COMPAGNON P, SEBAGH M, et al.Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgery[J]. HPB (Oxford), 2015, 17(7): 611-623.
[52] TORZILLI G, DONADON M, MARCONI M, et al.Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona clinic liver cancer classification: results of a prospective analysis[J]. Arch Surg, 2008, 143(11): 1082-1090.
[53] YANG T, LIN C, ZHAI J, et al.Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging[J]. J Cancer Res Clin Oncol, 2012, 138(7): 1121-1129.
[54] KOMATSU S, KIDO M, TANAKA M, et al.Clinical relevance of reductive hepatectomy for Barcelona clinic liver cancer stages B and C advanced hepatocellular carcinoma: a single-center experience of 102 patients[J]. World J Surg, 2019, 43(10): 2571-2578.
[55] PENG BG, HE Q, LI JP, et al.Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Am J Surg, 2009, 198(3): 313-318.
[56] CHOK KS, CHEUNG TT, CHAN SC, et al.Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis[J]. World J Surg, 2014, 38(2): 490-496.
[57] SHI J, LAI EC, LI N, et al.Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2010, 17(8): 2073-2080.
[58] 夏永祥,张峰,李相成,等. 原发性肝癌10 966例外科治疗分析[J]. 中华外科杂志,2021, 59(1):6-17.
[59] ZHANG W, LIU C, TAN Y, et al.Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: a propensity-matching cohort study[J]. Int J Surg, 2018, 54(Pt A): 259-264.
[60] LIU PH, HSIA CY, LEE YH, et al.Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma[J]. J Surg Oncol, 2015, 111(4): 404-409.
[61] GIANNINI EG, BUCCI L, GARUTI F, et al.Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice[J]. Hepatology, 2018, 67(5): 1784-1796.
[62] KOKUDO T, HASEGAWA K, MATSUYAMA Y, et al.Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion[J]. J Hepatol, 2016, 65(5): 938-943.
[63] CHOI C, CHOI GH, KIM TH, et al.Multimodality management for Barcelona clinic liver cancer stage C hepatocellular carcinoma[J]. Liver Cancer, 2014, 3(3-4):405-416.
[64] MAKARY MS, KHANDPUR U, CLOYD JM, et al.Locoregional therapy approaches for hepatocellular carcinoma: recent advances and management strategies[J]. Cancers (Basel), 2020, 12(7): 1914.
[65] MEHTA N.Hepatocellular carcinoma-How to determine therapeutic options[J]. Hepatol Commun, 2020, 4(3): 342-354.
[66] CHONG JU, CHOI GH, HAN DH, et al.Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2018, 25(11): 3308-3315.
[67] HAMAOKA M, KOBAYASHI T, KURODA S, et al.Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study[J]. Int J Surg, 2017, 44: 223-228.
[68] GOTO Y, HISAKA T, SAKAI H, et al.Salvage surgery for Initially unresectable locally advanced hepatocellular carcinoma downstaged by hepatic arterial infusion chemotherapy[J]. Anticancer Res, 2020, 40(8): 4773-4777.
[69] LEVI SANDRI GB, ETTORRE GM, COLASANTI M, et al.Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation[J]. Hepatobiliary Surg Nutr, 2017, 6(1): 44-48.
[70] HAN DH, JOO DJ, KIM MS, et al.Living donor liver transplantation for advanced hepatocellular carcinoma with portal vein tumor thrombosis after concurrent chemoradiation therapy[J]. Yonsei Med J, 2016, 57(5): 1276-1281.
[71] ZAYDFUDIM VM, VACHHARAJANI N, KLINTMALM GB, et al.Liver resection and transplantation for patients with hepatocellular carcinoma beyond Milan criteria[J]. Ann Surg, 2016, 264(4): 650-658.
[72] LEI J, WANG W, YAN L.Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria[J]. J Gastrointest Surg, 2013, 17(8): 1440-1446.
[73] CHAPMAN WC, GARCIA-AROZ S, VACHHARAJANI N, et al.Liver transplantation for advanced hepatocellular carcinoma after downstaging without up-front stage restrictions[J]. J Am Coll Surg, 2017, 224(4): 610-621.
[74] KARDASHIAN A, FLORMAN SS, HAYDEL B, et al.Liver transplantation outcomes in a U.S. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond Milan criteria[J]. Hepatology, 2020, 72(6): 2014-2028.
[75] EL-KHOUEIRY AB, SANGRO B, YAU T, et al.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
[76] ZHU AX, FINN RS, EDELINE J, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952.
[77] KUDO M, FINN RS, QIN S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[78] XU J, SHEN J, GU S, et al.Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
[79] LLOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
[80] CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[81] BRUIX J, QIN S, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66.
[82] ABOU-ALFA GK, MEYER T, CHENG AL, et al.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med, 2018, 379(1): 54-63.
[83] VILLADANGOS JA, SCHNORRER P.Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo[J]. Nat Rev Immunol, 2007, 7(7): 543-555.
[84] FERRARA N, HILLAN KJ, GERBER HP, et al.Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer[J]. Nat Rev Drug Discov, 2004, 3(5): 391-400.
[85] CHEN DS, MELLMAN I.Oncology meets immunology: the cancer-immunity cycle[J]. Immunity, 2013, 39(1): 1-10.
[86] MOTZ GT, SANTORO SP, WANG LP, et al.Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors[J]. Nat Med, 2014, 20(6): 607-615.
[87] GABRILOVICH DI, NAGARAJ S.Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol, 2009, 9(3): 162-174.
[88] GOEL S, DUDA DG, XU L, et al.Normalization of the vasculature for treatment of cancer and other diseases[J]. Physiol Rev, 2011, 91(3): 1071-1121.
[89] KERMICHE-RAHALI S, DI FIORE A, DRIEUX F, et al.Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib[J]. World J Surg Oncol, 2013, 11(1): 171.
[90] OHYA Y, HAYASHIDA S, TSUJI A, et al.Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy[J]. Surg Case Rep, 2020, 6(1): 318.
[91] TOMONARI T, SATO Y, TANAKA H, et al.Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: three case reports[J]. Medicine (Baltimore), 2020, 99(42): e22782.
[92] PARK JG, PARK SY, LEE HW.Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy[J]. World J Gastroenterol, 2015, 21(8): 2568-2572.
[93] NAKAMURA K, BEPPU T, HAYASHI H, et al.Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection[J]. Int Surg, 2015, 100(5): 908-914.
[94] YOSHIMOTO T, IMURA S, MORINE Y, et al.The outcome of sorafenib therapy on unresectable hepatocellular carcinoma: experience of conversion and salvage hepatectomy[J]. Anticancer Res, 2018, 38(1): 501-507.
[95] SCHWACHA-EIPPER B, MINCIUNA I, BANZ V, et al.Immunotherapy as a downstaging therapy for liver transplantation[J]. Hepatology, 2020, 72(4): 1488-1490.
[96] HO WJ, SHARMA G, ZHU Q, et al.Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy[J]. J Immunother Cancer, 2020, 8(2).
[97] 张雯雯,胡丙洋,韩骏,等. PD-1抑制剂与多靶点酪氨酸激酶抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告[J]. 中华肝胆外科杂志,2020,26(12):947-948.
[98] LENCIONI R, LLOVET JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60.
[99] CHERNYAK V, FOWLER KJ, KAMAYA A, et al.Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients[J]. Radiology, 2018, 289(3): 816-830.
[100] EISENHAUER EA, THERASSE P, BOGAERTS J, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[101] SUN DW, AN L, WEI F, et al.Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis[J]. Abdom Radiol (NY), 2016, 41(1): 33-41.
[102] HUANG C, ZHU XD, SHEN YH, et al.Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis[J]. Biomark Res, 2021, 9(1): 19.
[103] KUBOTA K, MAKUUCHI M, KUSAKA K, et al.Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors[J]. Hepatology, 1997, 26(5): 1176-1181.
[104] VAUTHEY JN, CHAOUI A, DO KA, et al.Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations[J]. Surgery, 2000, 127(5): 512-519.
[105] 卢实春,顾万清. 肝胆肿瘤外科治疗精准医学概要[J]. 中华肝胆外科杂志,2019,25(1):1-4.
[106] NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities Version 2[EB/OL].[2021-03-26]. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1486.
[107] 韩骏,卢实春. 晚期肝癌免疫与靶向降期转化治疗的几个要点讨论[J]. 中华肝胆外科杂志,2020,26(1):67-68.